Joe Lombardo
Governor

NEVADA HEALTH AUTHORITY
NEVADA MEDICAID
4070 Silver Sage Drive
Carson City, Nevada 89701
NVHA.NV.GOV

Stacie Weeks, Director

Ann Jensen, Administrator

Si necesitas ayuda traduciendo este mensaje, por favor escribe a dhcfp@dhcfp.nv.gov o llame (702) 668-4200 o (775) 687-1900 We will make reasonable accommodations for members of the public with a disability. Please notify Nevada Medicaid as soon as possible to dhcfp@dhcfp.nv.gov.

NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD

Date of Posting: September 17, 2025

Date of Meeting: October 16, 2025, at 1:00 PM

Name of Organization: The State of Nevada, Nevada Health Authority (NVHA), Nevada Medicaid, Drug Use Review Board (DUR)

Place of Meeting: Please use the teleconference/Microsoft Teams options provided below.

The physical location of this meeting which is open to the public at:

Hilton Garden Inn Reno
9920 Double R Blvd
Reno, NV 89502
(775) 850-9700

Please check with staff to verify room location.

Note: *If at any time during the meeting an individual who has been named on the agenda or has an item specifically regarding them included on the agenda is unable to participate because of technical or other difficulties, please email rxinfo@nvha.nv.gov and note at what time the difficulty started so that matters pertaining specifically to their participation may be continued to a future agenda if needed or otherwise addressed.*

Webinar: **October 2025 DUR Meeting**

(See final agenda page for full link or employ the shortened link directly above)

OR

https://tinyurl.com/847ch52a

Audio Only: **(844) 730-9010**

Event Number: **970 141 286#**

Joe Lombardo
Governor

NEVADA HEALTH AUTHORITY
NEVADA MEDICAID
4070 Silver Sage Drive
Carson City, Nevada 89701
NVHA.NV.GOV

Stacie Weeks, Director

Ann Jensen, Administrator

PLEASE DO NOT PUT THIS NUMBER ON HOLD (*hang up and rejoin if you must take another call*)

YOU MAY BE UNMUTED BY THE HOST WHEN SEEKING PUBLIC COMMENT, PLEASE HANG UP AND REJOIN IF YOU ARE HAVING SIDE CONVERSATIONS DURING THE MEETING

This meeting will be recorded to facilitate note-taking or other uses. By participating you consent to recording of your participation in this meeting.

AGENDA

1. Call to Order and Roll Call

2. General Public Comment

Public comment is encouraged to be submitted in advance so that it may be included in meeting materials and given attention. No action may be taken upon a matter raised through public comment unless the matter itself has been specifically included on an agenda as an action item. Please provide your name in any comment for record keeping purposes. You may submit comments in writing via e-mail to (rxinfo@nvha.nv.gov). There may be opportunity to take public comment via telephone or the meeting's virtual platform as well as in person opportunities, but phone participants should disconnect their call and re-join if they must take another call. Do not place your phone on hold or you may disrupt the meeting for other participants. Public comment may be limited to three minutes per person. ***Note: this guidance applies for all periods of public comment referenced further in the agenda, such as those related to clinical presentations****.*

Public comments may be related to topics on the agenda or matters related to other topics per NRS 241.020(3)(3)(II).

3. Administrative

a. **For Possible Action:** Review and Approve Updated Meeting Minutes from July 31, 2025.
b. Status Update by Nevada Medicaid.

4. Clinical Presentation

a. **For Possible Action:** Discussion and possible adoption of prior authorization and/or quantity limits for Hematopoietic/Hematinic Agents

i. Public comment on proposed clinical prior authorization criteria.
ii. Presentation of utilization and clinical information.
iii. Discussion by Board and review of utilization data.
iv. Proposed adoption of updated prior authorization criteria.

b. **For Possible Action:** Discussion and possible adoption of prior authorization and/or quantity limits for Reblozyl (luspatercept-aamt)

i. Public comment on proposed clinical prior authorization criteria.
ii. Presentation of utilization and clinical information.
iii. Discussion by Board and review of utilization data.
iv. Proposed adoption of updated prior authorization criteria.

c. **For Possible Action:** Discussion and possible adoption of prior authorization and/or quantity limits for CGRP Receptor Inhibitor medications

i. Public comment on proposed clinical prior authorization criteria.
ii. Presentation of utilization and clinical information.
iii. Discussion by Board and review of utilization data.
iv. Proposed adoption of updated prior authorization criteria.

d. **For Possible Action:** Discussion and possible adoption of prior authorization and/or quantity limits for metabolic dysfunction-associated steatohepatitis (MASH) agents

i. Public comment on proposed clinical prior authorization criteria.
ii. Presentation of utilization and clinical information.
iii. Discussion by Board and review of utilization data.
iv. Proposed adoption of updated prior authorization criteria.

e. **For Possible Action:** Discussion and possible adoption of prior authorization and/or quantity limits for Respirator and Allergy Biologics

i. Public comment on proposed clinical prior authorization criteria.
ii. Presentation of utilization and clinical information.
iii. Discussion by Board and review of utilization data.
iv. Proposed adoption of updated prior authorization criteria.

f. **For Possible Action:** Discussion and possible adoption of prior authorization and/or quantity limits for Topical Immunomodulators

i. Public comment on proposed clinical prior authorization criteria.
ii. Presentation of utilization and clinical information.
iii. Discussion by Board and review of utilization data.
iv. Proposed adoption of updated prior authorization criteria.

g. **For Possible Action:** Discussion and possible adoption of prior authorization and/or quantity limits for Eohilia (budesonide oral suspension)

i. Public comment on proposed clinical prior authorization criteria.
ii. Presentation of utilization and clinical information.
iii. Discussion by Board and review of utilization data.
iv. Proposed adoption of updated prior authorization criteria.

h. **For Possible Action:** Discussion and possible adoption of prior authorization and/or quantity limits for Prolate (oxycodone/acetaminophen)

i. Public comment on proposed clinical prior authorization criteria.
ii. Presentation of utilization and clinical information.
iii. Discussion by Board and review of utilization data.
iv. Proposed adoption of updated prior authorization criteria.

5. DUR Board Requested Reports

a. Opioid utilization-top prescribers, members, and pharmacies

i. Presentation of opioid criteria.
ii. Discussion by the Board and review of utilization data.

6. Standard DUR Reports

a. Review of Prescribing/Program Trends.

i. Top 10 Therapeutic Classes for Q1 and Q2 2025 (by Payment and by Claims)

b. Concurrent Drug Utilization Review (ProDUR).

i. Review of Q2 2025.
ii. Review of Top Encounters by Problem Type.

c. Retrospective Drug Utilization Review (RetroDUR)

i. Status of previous quarter.
ii. Status of current quarter.
iii. Review and discussion of responses.
iv. Recommendation for future topics.

7. Centers for Medicare and Medicaid Services (CMS) Annual Drug Utilization Review Surveys

a. Fee-for-Service Annual DUR Survey presented by Prime Therapeutics
b. Health Plan of Nevada (HPN) Annual DUR Survey presentation
c. SilverSummit Health Plan Annual DUR Survey presentation
d. Molina Annual DUR Survey presentation
e. Anthem/Elevance Blue Cross Blue Shield Healthcare Solutions Annual DUR Survey presentation

8. Clinical Presentations- Physician Administered Drugs (PAD)

a. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for aflibercept, Bavencio (avelumab), Beovu (brolucizumab-dbll), bevacizumab, Darzalex (daratumumab), Imfinzi (durvalumab), immune globulins IV, Jemperli (dostarlimab-gxly), Keytruda (pembrolizumab), Libtayo (cemiplimab-rwlc), Opdivo (nivolumab), paclitaxel albumin-bound, pemetrexed, ranibizumab, rituximab, immune globulins SC, Susvimo (ranibizumab), Tecentriq (atezolizumab), trastuzumab, Yervoy (ipilimumab)

i. Public comment on proposed clinical prior authorization criteria.
ii. Presentation of utilization and clinical information.
iii. Discussion by Board and review of utilization data.
iv. Proposed adoption of updated prior authorization criteria.

9. Closing Discussion

a. Public comment.

(No action may be taken upon a matter raised under public comment period unless the matter itself has been specifically included on an agenda as an action item. Comments will be limited to three minutes per person. Persons making comment will be asked to begin by stating their name for the record and to spell their last name.)

b. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comments will be limited to three minutes.

This notice and agenda have been posted online at http://dhcfp.nv.gov and http://notice.nv.gov as well as Carson City, Las Vegas, and Reno central offices for the Nevada Health Authority. Email notice has been made to such individuals as have requested notice of meetings (to request notifications please contact rxinfo@nvha.nv.gov, or at 4070 Silver Sage Drive, Carson City, NV 89701).

Nevada Medicaid, 1919 College Parkway, Suite 120, Carson City, Nevada 89706
Nevada Medicaid, 1010 Ruby Vista Drive, Suite 103, Elko, Nevada 89801
Nevada Medicaid, 1210 S. Valley View, Suite 104, Las Vegas, Nevada 89102
Nevada Medicaid, 745 W. Moana Lane, Suite 200, Reno, Nevada 89509

If you require a physical copy of supporting material for the public meeting, please contact rxinfo@nvha.nv.gov, or at 4070 Silver Sage Drive, Carson City, NV 89701. Limited copies of materials will also be available on site at the meeting's physical location. Supporting material will also be posted online at NV Medicaid Providers | DUR & SSS Boards.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make reasonable accommodations for members of the public with a disability and wish to participate. If accommodated arrangements are necessary, notify the Nevada Health Authority as soon as possible and at least ten days in advance of the meeting, by e-mail at rxinfo@nvha.nv.gov in writing, at 4070 Silver Sage Drive, Carson City, NV 89701.

Full Microsoft Teams Link:
https://events.teams.microsoft.com/event/7802a59f-7adf-4323-b9c3-6c5387e7ff67@34c95ba7-5ec6-4527-bc5e-b33b58104992